New diabetes program helps hill tribe elders control blood sugar
NCT ID NCT07669389
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a 6-week diabetes self-management program for ethnic minority elderly (aged 60+) in rural Thailand. The program included weekly group sessions on diet, exercise, medication, and emotional coping, plus two home visits. Researchers measured changes in blood sugar (HbA1c), self-management behaviors, and psychological distress after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Diabetes Self-Management Education (DSME) Program
- What this could lead to
- If successful, this program could offer a low-cost, culturally tailored way to help ethnic minority elderly better manage their diabetes and reduce emotional distress.
- What could go wrong
- This is a small, completed trial with only 108 participants and a short 12-week follow-up. Results may not apply to other populations or settings, and long-term benefits are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
108 people
The number who actually took part.
- Started
-
Nov 2025
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ethnic minority elderly aged 60 years or older residing in rural mountainous villages in Chiang Rai Province, Northern Thailand (including Akha, Lahu, Hmong, and Lisu communities) * Diagnosed with type 2 diabetes mellitus (T2DM) for at least one year * HbA1c level greater than 6.5% * Mini-Mental State Examination (MMSE) score of 24 or higher * Ability to communicate in Thai language * Willing and able to provide written informed consent or thumbprint with witness signature Exclusion Criteria: * Unable to complete the informed consent process * Mini-Mental State Examination (MMSE) score below 24, indicating possible cognitive impairment * Severe or unstable medical conditions that would preclude participation in a 6-week group education program (e.g., acute hospitalization, severe mobility limitations requiring full-time assistance) * Currently participating in another diabetes education or self-management intervention study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperglycemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sub-district Health Promoting Hospitals (SDHPHs), Chiang Rai Province
Chiang Rai, Changwat Chiang Rai, 57100, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a phone app ease the mental toll of childhood trauma?
- Can a simple risk score keep breast cancer patients on their targeted therapy?
- Four pills, one goal: can a new combo tame type 2 diabetes?
- Can banding the gut tame type 2 diabetes?
- Can QR codes and videos teach better foot care?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test